Overview
The 2025 ACC/AHA guideline for high blood pressure in adults retains key frameworks from 2017 while introducing new and revised recommendations spanning diagnosis, measurement, management, and specific clinical scenarios, providing updated, evidence-based guidance for hypertension practice.
Blood Pressure Categories and Measurement
- 2025 guideline retains the 2017 BP categories: normal (<120/80), elevated (120–129/<80), stage 1 (130–139/80–89), stage 2 (≥140/90).
- Differentiates BP categories for patients on/off antihypertensive medications (e.g., masked, white coat, controlled hypertension).
- Accurate measurement technique unchanged: avoid caffeine/exercise/smoking; proper rest, posture, room temperature; validated device; average two readings; results given verbally and in writing.
Laboratory and Diagnostic Recommendations
- No changes to initial labs for hypertension: CBC, electrolytes, creatinine, eGFR, lipid profile, glucose/HbA1C, TSH, urinalysis, protein/creatinine ratio, ECG.
Key New and Revised Recommendations
- Primary Aldosteronism: Screen all adults with resistant hypertension regardless of hypokalemia (Class 1); continue most antihypertensive meds (except MRA) before screening.
- Potassium Salt Substitutes: Recommend potassium-based salt substitutes for prevention/treatment of hypertension unless contraindicated by CKD or relevant medications (Class 2A).
- Stress Reduction: Transcendental meditation, breathing control, and yoga can be adjuncts for BP management (Class 2B).
- Risk-Based Treatment Thresholds: Use PREVENT equations for CVD risk estimation; initiate medications for SBP ≥130 or DBP ≥80 in select high-risk groups (CVD, diabetes, CKD, ≥7.5% 10-year risk).
- Stage 2 Hypertension: Prefer initial combination therapy (two agents, single pill); stepped care for stage 1 hypertension remains reasonable.
- Diabetes & CKD: ACE/ARB recommended for diabetes+CKD or albuminuria; upgraded to Class 1.
- Intracerebral Hemorrhage: Immediate BP lowering to 130–139 for 7 days if presenting with SBP 150–220; smooth control emphasized.
- Ischemic Stroke: Avoid lowering SBP <140 after endovascular treatment (Class 3-harm).
- Cognitive Impairment: Target BP <130 to prevent dementia (upgraded to Class 1).
Hypertension in Pregnancy
- Urgent antihypertensive therapy for BP ≥160/110 within 30–60 minutes.
- Treat chronic hypertension in pregnancy to <140/90.
- Low-dose aspirin recommended for preeclampsia prevention.
- Avoid atenolol, ACEI, ARB, direct renin inhibitors, nitroprusside, and MRA in pregnancy.
Resistant Hypertension and Renal Denervation
- Secondary evaluation includes reviewing interfering medications (Class 1).
- Renal denervation requires multidisciplinary evaluation; shared decision-making highlighted.
Severe Hypertension/Hypertensive Emergency
- "Severe hypertension" now preferred over "urgency."
- No acute use of IV/oral antihypertensive drugs in non-cardiac hospitalized patients with severe, asymptomatic hypertension (Class 3-harm).
Top 10 Take-Home Messages
- BP <130/80 is the target for all adults.
- Community and multidisciplinary team engagement is critical.
- BP classification, lifestyle changes, and proper measurement are foundational.
- Risk-based thresholds using PREVENT guide initiation and selection of drug therapy.
- Home BP monitoring with validated devices is emphasized.
- Severe hypertension in stable, non-pregnant patients is managed outpatient.
Decisions
- Continue 2017 BP categories and measurement methods.
- Screen for primary aldosteronism in all resistant hypertension.
- Adopt PREVENT risk equations for treatment decisions.
Recommendations / Advice
- Use potassium-based salt substitutes when appropriate.
- Incorporate stress reduction strategies as adjuncts.
- Prioritize combination therapy for stage 2 hypertension.
- Avoid rapid antihypertensive escalation in asymptomatic severe hypertension without end-organ damage.